• AB BioTechnologies New Monroe Co. Pharma Facility

    Construction is underway on Bloomington-based AB BioTechnologies $10.5 million pharmaceutical manufacturing facility in Monroe County. The 23,000 square-foot facility will be used to manufacture injectable drugs.

  • 16 Tech's New CEO

    A planned 60-acre innovation district on the near west side of Indianapolis has a new leader. 16 Tech has named Bob Coy its first president and CEO.

  • Lilly, Purdue Partner on Life Sciences Research

    Eli Lilly and Co. and Purdue University are forming a strategic life sciences research collaboration. Lilly will provide up to $52 million to fund research over five years, marking Purdue's largest strategic collaboration with a single company.

  • Health Commissioner Discusses Making Opioid Overdose Medication Available Without Prescription

    Tackling overdoses head-on. A lifesaving medication that can reverse opioid overdoses is now available without a prescription. State Health Commissioner Dr. Jerome Adams discusses the importance of Naloxone.

  • 16 Tech Announces First Leader

    Bob Coy has been named first president and chief executive officer of 16 Tech Community Corp. Coy most recently served as CEO of Ohio-based venture development organization CincyTech, which pumped more than $680 million into 70 different startups during his 11 years at the helm. Coy says his top priorities will include construction projects and the continued push for top interdisciplinary talent The 60-acre innovation community located near IUPUI.

  • Biomedical Innovation Center Director Talks Growth

    The Indiana Center for Biomedical Innovation has been a huge success with 11 startup companies under one roof creating an ecosystem for entrepreneurship, technology development and commercialization. The center’s director discusses its growth and plans for expansion.

  • Inside IU's Grand Challenges Winner

    The Precision Health Initiative is the winner of IU’s Grand Challenge. In the Business of Health, IU’s VP of Research shares how the initiative could transform health, medical research and education.

  • Quantum Leap Bridging Humanities and STEM

    Indiana Humanities is launching a new two-year initiative called “Quantum Leap.” CEO Keira Amstutz explains what happens when we bridge the humanities with STEM. 

  • Lilly CEO Details $850M Plans

    Eli Lilly and Co. is making an $850 million investment on manufacturing and research in the U.S. in 2017 and that includes Indianapolis. CEO Dave Ricks talks about what’s fueling the investment, and if more could be on the way.

  • Lilly Diabetes to Sponsor NASCAR

    What do Eli Lilly and Co. and NASCAR have in common? A lot, these days. The Indianapolis-based pharmaceutical company is expanding its partnership, signing a multi-year deal to become the “Official Diabetes Health Partner of NASCAR.”

  • Akanocure Pharmaceuticals Taking on Cancer

    Chemotherapeutic drugs may be taking a turn for the better. The husband and wife team of Akanocure Pharmaceuticals are working on developing anti-cancer chemotherapeutic drugs derived from natural sources.

  • Research Pegs Indiana's Life Sciences Impact at $63B

    The state's life sciences initiative says the industry's impact continues to get bigger. BioCrossroads says research from the Indiana Business Research Center at the Indiana University Kelley School of Business shows the industry's economic impact in 2015 rose to $63 billion. In all, more than 56,000 employees are tied to nearly 1,700 Indiana life sciences companies.

  • Women in Healthcare, Life Sciences Mentoring Program

    There is a scarcity of women leading healthcare and life science organizations in Indiana and across the U.S. Leaders from the Healthcare Businesswomen’s Association Indiana chapter are out to change that with a new mentoring program.   

  • How Upland's Sour Ale Mystery was Solved

    Bloomington-based Upland Brewing Co. was forced to dump 1,600 gallons of beer, because of a fermentation problem. We explain how an IU biochemist came to the rescue. 

  • 3D Bioprinter Used to Create Living Tissue

    Researchers at Indiana University are among the first in the US to use a 3D bioprinter to create living tissue. In the Business of Health, Barb Lewis explains when it could be used on humans.

  • Roche CEO: IBRI Will Succeed Where Others Have Failed

    The chief executive officer of Roche Diagnostic North America says Governor Eric Holcomb's endorsement of the Indiana Biosciences Research Institute is key to the collaboration that he believes will ultimately make the facility a global leader. Jack Phillips tells Inside INdiana Business the institute is about halfway to its $350 million funding goal. 

  • New Fat Replacement 'Epogee' Lands Major Customer

    Is it too good to be true? A former Dow AgroSciences and Lilly exec has developed a new fat replacement called Epogee that cuts calories, but keeps the taste. Choco Finesse has also landed a first major customer.

  • IU School of Medicine Professor's Research Heading to International Space Station

    Years of research by a professor at the IU School of Medicine is headed out of this world to the International Space Station! In the Business of Health, Barbara Lewis has more on what the mission could mean for the treatment ofosteoporosis. 

  • Purdue's $250M Life Sciences Investment

    Purdue is pumping $250 million into life sciences research. Executive Vice President For Research and Partnerships Suresh Garimella weighs-in on the impact the investment will have on both the university and the state.

  • Inside the Brown Center for Immunotherapy

    The IU School of Medicine receives its largest gift ever from an alum… $30 million! In the Business of Health, Barbara Lewis talks with tech pioneer Don Brown about the gift and a focus on immunotherapy.

  • Outgoing Lilly CEO Talks Triumphs, Disappointments

    Eli Lilly and Co. CEO John Lechleiter sits down for his last interview before leaving the drug maker’s top office. He talks about triumphs, the Alzheimer’s disappointment and what’s next for him and wife Sarah as they head into retirement.

  • Apexian Develops Pancreatic Cancer Drug

    Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. Barbara Lewis talks with the scientific founder of Apexian Pharmaceuticals about a drug that could make a difference.

  • New AgBiosciences Talent Report

    AgriNovus Indiana is out with a new report on talent. Find out why Indiana is in a good position, and where work needs to be done.

  • Roche's Major Upgrades, Commitment to Indy

    The first phase of a $300 million expansion at Indianapolis-based Roche Diagnostics Corp. is now complete. Hear from the Roche Group chairman, in town from Switzerland, on what he thinks about Indiana.

  • Elanco Establishing Itself as Industry Leader

    Greenfield-based Elanco U.S. Inc. has announced an agreement to add the companion animal vaccine portfolio of one of its competitors. The $885 million deal with Boehringer Ingelheim Vetmedica Inc. involves dozens of cat, dog and rabies vaccines, as well as an Iowa manufacturing facility. Shawn McKee, Elanco's Senior Director of Companion Animal U.S. explains what the planned acquisition will mean for the company. 

  • IBRI Hires European Bioscience Giant

    The Indiana Biosciences Research Institute has hired the man who will set the agenda for the research and innovation that comes out of the center. Rainer Fischer, who has been named chief scientific and innovation officer, most recently led the Fraunhofer Institute for Molecular Biology and Applied Ecology in Germany.

  • Indiana Conference Continues to Connect Life Sciences Industry to Businesses

    The Indiana Life Sciences Collaboration Conference Series kicked off 10 years ago. The popular event continues to serve as a major business connector for the Indiana life sciences industry.

  • Indiana Schools Provide Solution to EpiPen Price Controversy

    The price controversy over the EpiPen has Indiana physicians reminding parents of a recent state law that could help their children. Two years ago, state legislation allowed schools to get EpiPens for free.  

  • Inside Wild Pitch Yeast

    He’s a cancer researcher by day and a beer expert by night. Meet the IU scientist who’s launched Wild Pitch Yeast and is providing yeast to craft breweries making special Bicentennial-ales. 

  • 2016 ‘Indiana Companies to Watch’

    Fourteen businesses state-wide were recognized as the 2016 ‘Indiana Companies to Watch’. Newly appointed Indiana Economic Development Corporation Vice President and Chief Innovation Officer Ian Steff talks about the importance of the event to Governor Mike Pence’s $1 billion innovation and entrepreneurship initiative.

  • 2016 ‘Indiana Companies to Watch’

    Fourteen businesses state-wide were recognized as the 2016 ‘Indiana Companies to Watch’. Newly appointed Indiana Economic Development Corporation Vice President and Chief Innovation Officer Ian Steff talks about the importance of the event to Governor Mike Pence’s $1 billion innovation and entrepreneurship initiative.

  • Anthem-Cigna Merger Prompts Questions

    Indianapolis-based Anthem has announced plans to acquire Cigna for $54 Billion. IU McKinney School of Law Professor Dr. David Orentlicher discusses the details of the deal and what consumers can expect.
  • State Approves HIP 2.0

    The state of Indiana has received approval to implement HIP 2.0 instead of Medicaid. Indiana Hospital Association Vice President of Government Relations Brian Tabor explains the program, which offers health care access to 350,000 uninsured Hoosiers.
  • Lilly Diabetes Making 'Significant' Global Inroads

    Lilly Diabetes President Enrique Conterno says a recent $1 billion investment in insulin manufacturing, half of which is in central Indiana, is paying off. Conterno says the unit is making inroads in major global markets, including China and Japan.